-The Times of India Railway minister Dinesh Trivedi on Wednesday did what none of his predecessors had done for almost a decade - he hiked passenger fares across the board, following up on the increase in freight charges announced immediately after the recent round of assembly elections. While biting the bullet in hiking fares, he chose to couch the increase as ranging from a mere two paise per km for second class...

-Express News Service On Wednesday, Railway Minister Dinesh Trivedi lost his job for doing what two of his immediate predecessors — one of them his own party boss — could not. After 10 years, fares of passenger trains were finally increased in the rail budget that Trivedi presented, with the aim of pumping in much-needed funds into the financially ill national transport utility. Rolled out in two forms, the “fare rationalisation” models...

-PTI With agriculture share in GDP halving to 15 per cent in the last two decades, a government report card today called for major reforms, from marketing to investment, and new technologies for accelerating farm growth.  The report on 'State of Indian Agriculture 2011-12', tabled in the Lok Sabha said, "Achieving an 8-9 per cent rate of growth in overall gross domestic produce (GDP) may not deliver much in terms of poverty...

-The Business Standard The first agriculture survey, tabled in Parliament on Monday, called for more private participation to boost farm sector investments, rather than heavy doses of subsidies. “There is always a trade-off between allocating money through subsidies or by increasing investments. The investment option is much better than subsidies for sustaining long-term growth in agricultural production and also to reduce poverty faster,” said the survey, State of Indian Agriculture 2011-2012. It...

India's use of the compulsory licensing provision under its patents law for the first time to make the patented cancer drug Nexavar available at affordable prices is an essential, although belated step to curb the mounting cost of drugs. The grant of the licence by the Controller-General of Patents, Designs and Trade Marks to Natco Pharma for manufacture of the drug Sorafenib Tosylate (Nexavar) to treat liver and kidney cancer is...